Skip to main content
SpringerLink
Log in

Diagnostik und Therapie von Parkinson-Demenz in der klinischen Praxis

Diagnosis and clinical therapy for Parkinson’s disease

  • Übersicht
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

In den letzten Jahrzehnten erhielten bei der Parkinson-Erkrankung vornehmlich die motorischen Symptome und deren Therapie medizinische Beachtung. Jedoch rücken zunehmend auch nichtmotorische Symptome ins Bewusstsein; dazu gehören unter anderem kognitive Defizite. Eine Demenz im Rahmen einer Parkinson-Erkrankung ist häufiger als bislang angenommen. Nach durchschnittlich 8 Jahren werden bei ca. 40% der Parkinson-Patienten kognitive Defizite festgestellt. Die Demenz und die damit verbundenen Probleme bestimmen meist eher die Prognose der Parkinson-Erkrankung als die motorischen Symptome. Der Notwendigkeit einer standardisierten Diagnostik und adäquaten Therapie steht eine bislang geringe Studienlage gegenüber.

Summary

For decades, awareness of Parkinson’s disease mainly focused on the presence and treatment of motor symptoms. More and more other symptoms of this disease not related to the motor system now receive increased attention, including cognitive decline. Dementia in Parkinson’s disease occurs more often than initially was thought. After an average of 8 years, about 40% of these patients suffer from cognitive decline. The difficulties and related problems affect prognosis more than do the motor symptoms. There is a need for standardized diagnostic and specific therapeutic intervention, but appropriate studies are still lacking.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 18:937–941

    Article  PubMed  Google Scholar 

  2. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 10:1255–1263

    Article  Google Scholar 

  3. Andreasen N, Sjogren M, Blennow K (2003) CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 4:147–155

    Article  PubMed  Google Scholar 

  4. Athey RJ, Porter RW, Walker RW (2005) Cognitive assessment of a representative community population with Parkinson’s disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). Age Ageing 34:268–273

    Article  PubMed  Google Scholar 

  5. Bibl M, Mollenhauer B, Esselmann H et al. (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187

    Article  PubMed  Google Scholar 

  6. Braak H, Rub U, Jansen Steur EN et al. (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410

    PubMed  Google Scholar 

  7. Calabrese P, Kessler J (2000) DEMTECT. EISAI/Pfizer-Verlag, Karlsruhe

  8. Cummings JL (1988) Intellectual impairment in Parkinson’s disease: clinical, pathologic and biochemical correlates. J Geriatr Psychiatry Neurol 1:24–36

    PubMed  Google Scholar 

  9. El-Agnaf OM, Salem SA, Paleologou KE et al. (2003) Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 17:1945–1947

    PubMed  Google Scholar 

  10. Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2:229–237

    Article  PubMed  Google Scholar 

  11. Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 24:2509–2518

    Article  Google Scholar 

  12. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental-State. A practical method for grading the mental state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  PubMed  Google Scholar 

  13. Gomez-Tortosa E, Gonzalo I, Fanjul S et al. (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 60:1218–1222

    Article  PubMed  Google Scholar 

  14. Hughes TA, Ross HF, Mindham RH et al. (2004) Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 110:118–123

    Article  PubMed  Google Scholar 

  15. Jellinger KA, Seppi K, Wenning GK et al. (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339

    Article  PubMed  Google Scholar 

  16. Kalbe E, Kessler J, Emmens D et al. (2005) PANDA. Ökonomische Erfassung kognitiver und affektiver Beeinträchtigungen bei der Parkinson Demenz. Akt Neurol 32(Suppl 4):223

    Google Scholar 

  17. Klein C (2006) Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 63:328–334

    Article  PubMed  Google Scholar 

  18. Langston JW (2006) The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59:591–596

    Article  PubMed  Google Scholar 

  19. McKeith IG, Del Ser T, Spano P et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 356:2031–2036

    Article  PubMed  Google Scholar 

  20. McKeith IG, Dickson DW, Lowe J et al. (2005) Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 65:1863–1872

    Article  PubMed  Google Scholar 

  21. Mollenhauer B, Cepek L, Bibl M et al. (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19:164–170

    Article  PubMed  Google Scholar 

  22. Parkinson J (1817) An essay on the shaking palsy. Neely & Jones, London

  23. Parkkinen L, Kauppinen T, Pirttila T et al. (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91

    Article  PubMed  Google Scholar 

  24. Press DZ (2004) Parkinson’s Disease dementia – A First step. N Engl J Med 24:2547

    Article  Google Scholar 

  25. Ravina B, Siderowf A, Farrar JT et al. (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crosssover study. J Neurol Neurosurg Psychiatry 76:934–939

    Article  PubMed  Google Scholar 

  26. Riedel O, Dodel R, Spottke A et al. (2006) Wie beurteilen Ärzte die Häufigkeit demenzieller, depressiver und psychotischer Syndrome bei Patienten mit der Parkinson-Krankheit?—Eine Befragung von 500 Fachärzten im ambulanten Versorgungssektor Deutschlands. Akt Neurol 33: 374–380

    Article  Google Scholar 

  27. Rosenstein LD (1998) Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev 8:109–167

    Article  PubMed  Google Scholar 

  28. Roth M, Huppert FA, Mountjoy CQ et al. (1999) CAMDEX—Revised. Cambridge University Press, Cambridge

  29. Shulman KI, Shedletsky R, Silver IL (1986) The challenge of time: clockdrawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1:135–140

    Article  Google Scholar 

  30. Sinanovic O, Kapidzic A, Kovacevic L et al. (2005) EEG frequency and cognitive dysfunction in patients with Parkinson’s disease. Med Arh 59:286–287

    PubMed  Google Scholar 

  31. Spillantini MG, Schmidt ML, Lee VM et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840

    Article  PubMed  Google Scholar 

  32. WHO (2005) Weltgesundheitsorganisation: Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F), 5. durchgesehene und ergänzte Auflage. Huber, Bern

  33. Wiltfang J, Lewczuk P, Riederer P et al. (2005) Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 6:69–84

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

    B. Mollenhauer

  2. Paracelsus-Elena-Klinik, Klinikstraße 16, 34128, Kassel, Deutschland

    S. Wenzel, B. Mollenhauer & C. Trenkwalder

Authors
  1. S. Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Mollenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Trenkwalder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Wenzel.

Additional information

B.M. wird finanziell unterstützt von der Michael J. Fox Foundation, der American Parkinson Disease Association und durch ein Dr. Werner Jackstädt-Stipendium (Stifterverband der Deutschen Wissenschaft).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wenzel, S., Mollenhauer, B. & Trenkwalder, C. Diagnostik und Therapie von Parkinson-Demenz in der klinischen Praxis. Nervenarzt 77, 1439–1443 (2006). https://doi.org/10.1007/s00115-006-2179-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-006-2179-7

Schlüsselwörter

Keywords

Search

Navigation